



Mr. Yogesh Agrawal

MANAGING DIRECTOR

Mr. Yogesh Agrawal is the Managing Director of Ajanta Pharma Limited, a leading and dynamic pharmaceutical company in India.

Under his leadership, Ajanta Pharma has expanded its presence significantly, serving the Indian Pharma Market and operating in over 33 countries, including the US, Africa, CIS, West Asia, Southeast Asia, and the Middle East.

Mr. Agrawal holds a degree in Business Management from Johnson & Wales University, USA. He joined Ajanta Pharma in 1996 and, at the age of just 30, began heading the company, which was still a relatively small enterprise.

Over the past 24 years, Mr. Agrawal, alongside his younger brother Rajesh Agrawal, has transformed Ajanta Pharma into a pharmaceutical powerhouse. The company's sales turnover soared from ₹ 85 crore to ₹ 5,453 crore, reflecting a compound annual growth rate (CAGR) of over 19%. The Profit After Tax (PAT) during this period increased at a CAGR of 37% to Rs. 1,056 crore, while the market capitalization surged from ₹ 24 crore to an impressive ₹ 35,000 crore.

Mr. Agrawal has spearheaded the establishment of five new large-scale manufacturing plants and significantly expanded the company's R&D capabilities, which now include over 850 scientists dedicated to innovation and product development.

Throughout his illustrious career, Mr. Agrawal has been honoured with numerous prestigious awards. Among the most notable are the TIME Magazine "Young Maker of the Year" award, presented by the Honourable Prime Minister of India, Mr. Narendra Modi. He was also named "CEO of the Year - Next Gen" by CNBC and recognized by Hurun India as one of the "Next Gen Leaders of the Year 2023." In addition, he was nominated for the "Forbes Leadership Award" and featured in Business Today's list of the 100 Most Valuable CEOs.

Today, Ajanta Pharma operates seven state-of-the-art manufacturing facilities, including two approved by the US FDA, and runs a cutting-edge R&D centre. The company employs over 13,000 people worldwide and reinvests about 5% of its revenue into research and development, underscoring its commitment to innovation and excellence.

FOLLOW US ON

